Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYOBI study of obinutuzumab in rituximab-refractory or rituximab-intolerant non-infectious active cryoglobulinemia vasculitis
2023-508930-33-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in cryoglobulinaemia, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete clinical response at 6 months. Planned start Oct 2025; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
cryoglobulinaemia
Beyond the preview
Go deeper on 2023-508930-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508930-33-00.